Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
Jun 23, 2016
CAMBRIDGE, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016.  Dr. Gilman was most recently Executive Vice P...
Jun 9, 2016
CAMBRIDGE, Mass., June 09, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the dosing of the first healthy volunteers in a Phase 1 randomized, double-blind, placebo-controlled, ascending-dose cohort study to evaluat...
Jun 8, 2016
CAMBRIDGE, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company's lead biosimilar candidate developed in collaboration with Baxalta, ...
Jun 4, 2016
CAMBRIDGE, Mass., June 04, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today presented final data from the Phase 1 trial evaluating necuparanib in combination with nab-paclitaxel (nabP; Abraxane®) and gemcitabine (gem) in ...
May 25, 2016
CAMBRIDGE, Mass., May 25, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Goldman Sachs 37th Annual Healthcare Conference will be webcast on Wednesday, June 8th at 8 a.m. PT. The au...
May 19, 2016
CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of its final results from the Phase 1 study of its drug candidate, necuparanib, in patients with metastatic pancrea...
May 3, 2016
CAMBRIDGE, Mass., May 03, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2016. For the first quarter of 2016, the Company reported total revenues of $19.9 million, including $14.8 million in product revenues from Sandoz's sale of Glatopa® (g...
Apr 26, 2016
CAMBRIDGE, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), announced today that is has changed the time for its first quarter 2016 earnings conference call and webcast. Momenta will now host its conference call and webcast at 9:00 a.m. EDT on Tuesday, May 3, 2016.    To access the call, please dial (877) ...
Apr 25, 2016
CAMBRIDGE, Mass., April 25, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.Deutsche Bank 41st Annua...
Apr 19, 2016
CAMBRIDGE, Mass., April 19, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2016 before the U.S. financial markets open on Tuesday, May 3, 2016. Manageme...
1
...
NextLast
= add release to Briefcase